Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Free Cash Flow (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Free Cash Flow for 3 consecutive years, with -$7.7 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 18.45% to -$7.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$31.0 million through Dec 2025, up 5.61% year-over-year, with the annual reading at -$31.0 million for FY2025, 5.61% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$7.7 million at Mereo BioPharma, down from -$7.3 million in the prior quarter.
  • The five-year high for Free Cash Flow was $2.7 million in Q3 2023, with the low at -$9.4 million in Q4 2024.
  • Average Free Cash Flow over 3 years is -$7.1 million, with a median of -$7.7 million recorded in 2023.
  • The sharpest move saw Free Cash Flow tumbled 382.78% in 2024, then increased 18.45% in 2025.
  • Over 3 years, Free Cash Flow stood at -$6.8 million in 2023, then plummeted by 38.75% to -$9.4 million in 2024, then grew by 18.45% to -$7.7 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$7.7 million, -$7.3 million, and -$7.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.